ResearchMoz added Latest Research Report titled " Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape " to it's Large Report database.
Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape
Summary
Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distribution. Acute HCV infection is usually asymptomatic, and 15-45% of people spontaneously clear the virus within six months of infection without any treatment, while the remaining 55-85% develop chronic HCV infection.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1313842
The hepatitis C market is currently dominated by high-performance regimens comprising new-generation DAAs. The treatment algorithms have shifted away rapidly from interferon-based therapies, and towards interferon-free DAA combination therapies that can cure most patients in as little as eight to 12 weeks, without ribavirin. In the highly competitive hepatitis C treatment landscape, where new combination therapies match each other closely in terms of safety and efficacy, one key differential is patient segment coverage. A number of factors that have conventionally been used to predict treatment outcome, including HCV genotypes, previous treatment history, and a patients liver and kidney conditions, are also used to define target patient populations for new therapies.
The late-stage hepatitis C pipeline is predominantly composed of DAA regimens targeting HCV NS5A, NS5B polymerase, and NS3/4A protease. The most advanced of the promising pipeline agents are Gileads sofosbuvir/velpatasvir/voxilaprevir and AbbVies glecaprevir/pibrentasvir, which have been studied in Phase III clinical trials. Due to the highly effective late-stage pipeline drugs and marketed products, developers of HCV NS5A, NS5B polymerase and NS3/4A protease in earlier stages of clinical development are not aiming to dominate the market, but rather to earn a place as a me too product.
Browse more details @ http://www.researchmoz.us/hepatitis-c-therapeutics-in-asia-pacific-markets-to-2023-presence-of-outstanding-direct-acting-antivirals-and-late-stage-pipeline-to-transform-the-clinical-and-commercial-landscape-report.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 12
2.4 HCV Life Cycle 13
2.4.1 NS3/NS4A Protease 13
2.4.2 NS5A 13
2.4.3 NS5B Polymerase 13
2.5 Etiology and Pathophysiology 13
2.5.1 Pathophysiology 14
2.6 Diagnosis 18
2.7 Disease Progression 18
2.7.1 Acute Stage 18
2.7.2 Chronic Stage 19
2.7.3 End Stage 19
2.7.4 Factors Affecting Progression 19
2.7.5 Co-morbidities and Complications 20
2.8 Prognosis 20
2.9 Treatment Options and Treatment Algorithm 21
2.9.1 Treatment Options 21
2.9.2 Treatment Algorithm 25
2.9.3 Non-pharmacological Treatments 27
3 Marketed Products 29
3.1 Overview 29
3.2 Single Component Direct-Acting Antivirals 30
3.2.1 Sovaldi (Sofosbuvir) - Gilead Sciences 30
3.2.2 Daklinza (Daclatasvir) - Bristol-Myers Squibb 31
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape
Summary
Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distribution. Acute HCV infection is usually asymptomatic, and 15-45% of people spontaneously clear the virus within six months of infection without any treatment, while the remaining 55-85% develop chronic HCV infection.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1313842
The hepatitis C market is currently dominated by high-performance regimens comprising new-generation DAAs. The treatment algorithms have shifted away rapidly from interferon-based therapies, and towards interferon-free DAA combination therapies that can cure most patients in as little as eight to 12 weeks, without ribavirin. In the highly competitive hepatitis C treatment landscape, where new combination therapies match each other closely in terms of safety and efficacy, one key differential is patient segment coverage. A number of factors that have conventionally been used to predict treatment outcome, including HCV genotypes, previous treatment history, and a patients liver and kidney conditions, are also used to define target patient populations for new therapies.
The late-stage hepatitis C pipeline is predominantly composed of DAA regimens targeting HCV NS5A, NS5B polymerase, and NS3/4A protease. The most advanced of the promising pipeline agents are Gileads sofosbuvir/velpatasvir/voxilaprevir and AbbVies glecaprevir/pibrentasvir, which have been studied in Phase III clinical trials. Due to the highly effective late-stage pipeline drugs and marketed products, developers of HCV NS5A, NS5B polymerase and NS3/4A protease in earlier stages of clinical development are not aiming to dominate the market, but rather to earn a place as a me too product.
Browse more details @ http://www.researchmoz.us/hepatitis-c-therapeutics-in-asia-pacific-markets-to-2023-presence-of-outstanding-direct-acting-antivirals-and-late-stage-pipeline-to-transform-the-clinical-and-commercial-landscape-report.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 12
2.4 HCV Life Cycle 13
2.4.1 NS3/NS4A Protease 13
2.4.2 NS5A 13
2.4.3 NS5B Polymerase 13
2.5 Etiology and Pathophysiology 13
2.5.1 Pathophysiology 14
2.6 Diagnosis 18
2.7 Disease Progression 18
2.7.1 Acute Stage 18
2.7.2 Chronic Stage 19
2.7.3 End Stage 19
2.7.4 Factors Affecting Progression 19
2.7.5 Co-morbidities and Complications 20
2.8 Prognosis 20
2.9 Treatment Options and Treatment Algorithm 21
2.9.1 Treatment Options 21
2.9.2 Treatment Algorithm 25
2.9.3 Non-pharmacological Treatments 27
3 Marketed Products 29
3.1 Overview 29
3.2 Single Component Direct-Acting Antivirals 30
3.2.1 Sovaldi (Sofosbuvir) - Gilead Sciences 30
3.2.2 Daklinza (Daclatasvir) - Bristol-Myers Squibb 31
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
No comments:
Post a Comment